Project Grant R01CA301535
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $758K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Cancer Institute, within the Department of Health and Human Services, awarded the University of Oklahoma Health Sciences Center $606,142 on August 1, 2026, to conduct a fully powered randomized controlled trial testing a novel mobile messaging intervention designed to increase smoking quit attempts and cessation among adults who initially report not being ready to quit smoking within thirty days. The intervention, called PHOENIX, delivers daily text messages tailored to...
- The National Cancer Institute of the National Institutes of Health awarded the University of Southern California $426,828 on July 6, 2026, through the Cancer Cause and Prevention Research program (CFDA 93.393) to test regulatory strategies promoting e-cigarette cessation among young adults. The University of Southern California will conduct a study using a simulated vape shop experimental laboratory space ("The Puff Point") to evaluate two innovative policy interventions designed to...
- The National Cancer Institute awarded Washington State University $560,858 on July 21, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial evaluating a remote telehealth intervention combining varenicline and app-based contingency management for rural smokers with alcohol use disorder. The trial will enroll 192 rural smokers seeking smoking cessation treatment and living with an alcohol use disorder. Participants will be...
- The National Institutes of Health National Cancer Institute awarded The Medical University of South Carolina $586,018 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a three-arm clinical trial testing augmented doses of nicotine replacement therapy for individuals who use both combustible cigarettes and e-cigarettes and wish to quit both products. The trial will randomize dual-use participants to receive behavioral support combined with...
- The National Cancer Institute awarded New York University $310,185 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and feasibility-test a mobile application delivering an evidence-based intervention that addresses financial stress and smoking cessation. The recipient will develop a smartphone app version of the FIERCE (Financial Freedom from Cigarettes) intervention, which integrates financial coaching into smoking cessation treatment. The work...
- The National Cancer Institute awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $948,630 under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 1, 2026, for a naturalistic cohort study examining the real-world effectiveness of smoking cessation aids in US adults. The project will conduct a longitudinal survey study using the Understanding America Study, a nationally representative panel of 20,000 US...
- Grant Award Summary Duke University received a $906,306 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded September 11, 2025, with completion targeted for August 31, 2028. The award funds development and testing of a telehealth-delivered, cue-based treatment intervention designed to promote smoking cessation among people who smoke lightly (PSLI), defined as those smoking 10 cigarettes per day or fewer. Building...
- The National Cancer Institute, an operating division of the Department of Health and Human Services, awarded Chapman University $649,603 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the TRAQ-TO-QUIT smoking cessation intervention study. The research combines three evidence-based approaches into a multilevel intervention: pediatrician-initiated brief advice and referral to cessation services; novel behavioral tele-counseling to guide smokers...
- The National Institute on Drug Abuse awarded The Trustees of Columbia University in the City of New York $1,163,086 on April 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized controlled trial of the SENSE2QUIT app, a sensor-enabled mobile health intervention for smoking cessation in people with HIV. The project will enhance the app's technical capabilities—improving smartwatch-based gesture detection accuracy, data transmission stability, and...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $177,500 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to adapt and evaluate a community navigator-led tobacco cessation intervention for cancer patients experiencing food insecurity. The project, titled QUITTRACK, addresses the elevated rate of tobacco dependence among food-insecure cancer patients—44 percent of cancer patients who smoke experience food insecurity,...